Evolution of RAS Mutational Status in Liquid Biopsies During First-Line Chemotherapy for Metastatic Colorectal Cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Evolution of RAS Mutational Status in Liquid Biopsies During First-Line Chemotherapy for Metastatic Colorectal Cancer
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-07-16
DOI
10.3389/fonc.2020.01115
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer
- (2019) Cristina Raimondi et al. Cancers
- P-089FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial
- (2019) A Fernández Montes et al. ANNALS OF ONCOLOGY
- Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer
- (2019) Emilie Moati et al. INTERNATIONAL JOURNAL OF CANCER
- Multiclonal tumor origin: Evidence and implications
- (2018) Barbara L. Parsons MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH
- Significance of Liquid Biopsy for Monitoring and Therapy Decision of Colorectal Cancer
- (2018) Susanne Klein-Scory et al. Translational Oncology
- Cross-platform comparison for the detection of RAS mutations in cfDNA (ddPCR Biorad detection assay, BEAMing assay, and NGS strategy)
- (2018) Jessica Garcia et al. Oncotarget
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial
- (2018) Khurum H. Khan et al. Cancer Discovery
- 543PGene mutation status in circulating tumor DNA (ctDNA) and first-line FOLFOXIRI plus bevacizumab (bev) in metastatic colorectal cancer (mCRC) harboring RAS mutation
- (2018) Y Sunakawa et al. ANNALS OF ONCOLOGY
- Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer
- (2018) Jesús García-Foncillas et al. BRITISH JOURNAL OF CANCER
- Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan
- (2018) Chiara Cremolini et al. JAMA Oncology
- The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials
- (2017) Julian Walter Holch et al. EUROPEAN JOURNAL OF CANCER
- Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer
- (2017) Cristina Santos et al. MOLECULAR CANCER THERAPEUTICS
- Blood-based detection ofRASmutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-basedRAStesting
- (2017) Wolff Schmiegel et al. Molecular Oncology
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
- (2016) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centres
- (2016) Annemarie Boleij et al. BMC CANCER
- Utility ofKRASmutation detection using circulating cell-free DNA from patients with colorectal cancer
- (2016) Takeshi Yamada et al. CANCER SCIENCE
- A Study of Hypermethylated Circulating Tumor DNA as a Universal Colorectal Cancer Biomarker
- (2016) S. Garrigou et al. CLINICAL CHEMISTRY
- Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy
- (2016) John M. Findlay et al. Nature Communications
- Kirsten Ras* oncogene: Significance of its discovery in human cancer research
- (2016) Nobuo Tsuchida et al. Oncotarget
- Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab
- (2016) Rodrigo A. Toledo et al. Oncotarget
- Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment
- (2015) M. P. Morelli et al. ANNALS OF ONCOLOGY
- MethyLight droplet digital PCR for detection and absolute quantification of infrequently methylated alleles
- (2015) Ming Yu et al. Epigenetics
- Metastatic Colorectal Cancer: Current State and Future Directions
- (2015) Marwan G. Fakih JOURNAL OF CLINICAL ONCOLOGY
- Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment andRASMutations in Colorectal Cancer
- (2015) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
- (2015) Giulia Siravegna et al. NATURE MEDICINE
- Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution
- (2015) Shaoping Ling et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Clinical Relevance of KRAS-Mutated Subclones Detected with Picodroplet Digital PCR in Advanced Colorectal Cancer Treated with Anti-EGFR Therapy
- (2014) P. Laurent-Puig et al. CLINICAL CANCER RESEARCH
- Changes in mutational status during third-line treatment for metastatic colorectal cancer-Results of consecutive measurement of cell free DNA,KRASandBRAFin the plasma
- (2014) Karen-Lise Garm Spindler et al. INTERNATIONAL JOURNAL OF CANCER
- Aberrant methylation of NPY, PENK, and WIF1 as a promising marker for blood-based diagnosis of colorectal cancer
- (2013) Jean-Pierre Roperch et al. BMC CANCER
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
- (2013) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
- (2012) H. J. Schmoll et al. ANNALS OF ONCOLOGY
- A Comprehensive Survey of Ras Mutations in Cancer
- (2012) I. A. Prior et al. CANCER RESEARCH
- Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon
- (2008) Kevin M Haigis et al. NATURE GENETICS
- DNA methylation analysis by digital bisulfite genomic sequencing and digital MethyLight
- (2008) D. J. Weisenberger et al. NUCLEIC ACIDS RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search